|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016778,
umls-concept:C0017262,
umls-concept:C0024623,
umls-concept:C0040085,
umls-concept:C0185117,
umls-concept:C0205251,
umls-concept:C0332293,
umls-concept:C0677930,
umls-concept:C0681842,
umls-concept:C1333602,
umls-concept:C1516213,
umls-concept:C1521996,
umls-concept:C1522673,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-6-25
|
|
pubmed:abstractText |
To assess the thymidylate synthase protein (TS) in tumor cells of resected gastric cancer patients treated with adjuvant tegafur (TG), we reviewed the outcome of 94 randomized patients treated either with adjuvant TG plus mitomycin C (MMC) or MMC alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Mitomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
226-33
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15218314-Adenocarcinoma,
pubmed-meshheading:15218314-Adult,
pubmed-meshheading:15218314-Aged,
pubmed-meshheading:15218314-Antibiotics, Antineoplastic,
pubmed-meshheading:15218314-Antibodies, Monoclonal,
pubmed-meshheading:15218314-Antimetabolites, Antineoplastic,
pubmed-meshheading:15218314-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15218314-Chemotherapy, Adjuvant,
pubmed-meshheading:15218314-Disease-Free Survival,
pubmed-meshheading:15218314-Female,
pubmed-meshheading:15218314-Follow-Up Studies,
pubmed-meshheading:15218314-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:15218314-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15218314-Humans,
pubmed-meshheading:15218314-Immunohistochemistry,
pubmed-meshheading:15218314-Male,
pubmed-meshheading:15218314-Medical Records,
pubmed-meshheading:15218314-Middle Aged,
pubmed-meshheading:15218314-Mitomycin,
pubmed-meshheading:15218314-Predictive Value of Tests,
pubmed-meshheading:15218314-Randomized Controlled Trials as Topic,
pubmed-meshheading:15218314-Retrospective Studies,
pubmed-meshheading:15218314-Stomach Neoplasms,
pubmed-meshheading:15218314-Survival Analysis,
pubmed-meshheading:15218314-Tegafur,
pubmed-meshheading:15218314-Thymidylate Synthase,
pubmed-meshheading:15218314-Treatment Outcome,
pubmed-meshheading:15218314-Tumor Markers, Biological
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
|
|
pubmed:affiliation |
Oncology Department, Hospital Clinic, Institute of Hemato-Oncology, University of Barcelona, Barcelona, Spain. jjgrau@medicina.ub.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
